Search Results

Sixteen-Year Follow-up Study Reinforces Betaseron(R) Long-Term Efficacy, Safety and Tolerability in Multiple Sclerosis.

• Source: PR Newswire. April 4, 2006

Record details

U.S. Approves a Drug For Multiple Sclerosis

• Source: The New York Times. July 24, 1993

Record details

Bayer Updates Betaseron (interferon beta-1b) Prescribing Information in Accordance with the U.S. Food and Drug Administration's Pregnancy and Lactation Labeling Rule

• Source: PR Newswire. Dec 17, 2018

Record details

Teaching With MS

• Authors : Peck, Lee Anne

• Source: The Chronicle of Higher Education. August 5, 2005, Vol. 51 Issue 48,

Record details

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth.

• Source: PR Newswire. Sept 16, 2013

Record details

Commercial Insight: Multiple Sclerosis - Next Generation Therapies Signal the Start of a New Era.

• Source: PR Newswire. Nov 8, 2010

Record details

Reportlinker Adds Commercial Insight: Multiple Sclerosis - Next Generation Therapies Signal the Start of a New Era.

• Source: PR Newswire. August 10, 2010

Record details

Does the MS Market Need Another Interferon? Neurologists Provide Insight in the Wave One Report of LaunchTrends: EXTAVIA.

• Source: PR Newswire. Jan 11, 2010

Record details

Experimental drug slows advance of multiple sclerosis

• Source: Globe & Mail (Toronto, Canada). October 11, 1994, A2

Record details

COPAXONE Showed Greatest Reduction in Long-Term Relapse Rate Among MS Treatments.

• Source: PR Newswire. June 21, 2005

Record details